RWD74 USE OF RWE TO INFORM SURVIVAL EXTRAPOLATION IN HEALTH ECONOMIC APPRAISALS OF CANCER DRUGS IN SWEDEN: A REVIEW OF NATIONAL HEALTH ECONOMIC REPORTS 2010-2024
Long-term survival predictions in health economic assessments of cancer drugs, typically based on clinical trials, are often associated with considerable uncertainty. To reduce uncertainty, several health technology assessment (HTA) agencies recommend incorporating real-world evidence (RWE) to inform or validate survival extrapolations. Within the SURPASS project, we examine the accuracy of survival predictions and how they can be improved in cost-effectiveness analyses. This sub-study specifically reviews whether, and how, RWE has been used to inform survival extrapolations in the Swedish Dental and Pharmaceutical Benefits Agency’s (TLV) cancer drug assessments.
Authors
- Niklas Zethraeus (ORCID: https://orcid.org/0000-0003-4036-6966)
- Sophie Langenskiöld (ORCID: https://orcid.org/0000-0003-3888-2910)
- Sigrid Klaar
- Emma Söreskog (ORCID: https://orcid.org/0000-0003-1302-387X)
- Mariam Kasrashvili
Institutions
- Uppsala University (SE)
- Karolinska Institutet (SE)
Publication Details
- Journal
- Value in Health Regional Issues
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.vhri.2025.101304
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00